ABCG2: A perspective

被引:354
|
作者
Robey, Robert W. [1 ]
To, Kenneth K. K. [1 ]
Polgar, Orsolya [1 ]
Dohse, Marius [1 ]
Fetsch, Patricia [2 ]
Dean, Michael [3 ]
Bates, Susan E. [1 ]
机构
[1] NCI, Med Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] Natl Canc Inst, Lab Genom Divers, Frederick, MD 21702 USA
关键词
ABCG2; BCRP; Drug-resistance; ABC transporter; Chemotherapy; Pharmacology; CANCER-RESISTANCE-PROTEIN; HUMAN MULTIDRUG TRANSPORTER; LIMITS FETAL DISTRIBUTION; HIGH-AFFINITY INTERACTION; BLOOD-BRAIN-BARRIER; CARCINOMA CELL-LINE; P-GLYCOPROTEIN; IMATINIB MESYLATE; BILIARY-EXCRETION; BCRP ABCG2;
D O I
10.1016/j.addr.2008.11.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
ABCG2, or breast cancer resistance protein (BCRP), is an ABC transporter that has been the subject of intense study since its discovery a decade ago. With high normal tissue expression in the brain endothelium, gastrointestinal tract, and placenta, ABCG2 is believed to be important in the protection from xenobiotics, regulating oral bioavailability, forming part of the blood-brain barrier, the blood-testis barrier, and the maternal-fetal barrier. Notably, ABCG2 is often expressed in stem cell populations, where it likely plays a role in xenobiotic protection. However, clues to its epigenetic regulation in various cell populations are only beginning to emerge. While ABCG2 overexpression has been demonstrated in cancer cells after in vitro drug treatment, endogenous ABCG2 expression in certain cancers is likely a reflection of the differentiated phenotype of the cell of origin and likely contributes to intrinsic drug resistance. Notably, research into the transporter's role in cancer drug resistance and its development as a therapeutic target in cancer has lagged. Substrates and inhibitors of the transporter have been described, among them chemotherapy drugs, tyrosine kinase inhibitors, antivirals, HMG-CoA reductase inhibitors, carcinogens, and flavonoids. This broad range of substrates complements the efficiency of ABCG2 as a transporter in laboratory studies and suggests that, while there are redundant mechanisms of xenobiotic protection, the protein is important in normal physiology. indeed, emerging studies in pharmacology and toxicology assessing polymorphic variants in man, in combination with murine knockout models have confirmed its dynamic role. Work in pharmacology may eventually lead us to a greater understanding of the physiologic role of ABCG2. (C) 2008 Published by Elsevier B.V.
引用
收藏
页码:3 / 13
页数:11
相关论文
共 50 条
  • [21] Imatinib and ABCG2: who controls whom?
    Melo, Junia V.
    [J]. BLOOD, 2006, 108 (04) : 1116 - 1117
  • [22] Identification and characterization of ABCG2 enhancer regions
    Eclov, Rachel J.
    Ahituv, Nadav
    Kroetz, Deanna L.
    [J]. DRUG METABOLISM REVIEWS, 2011, 43 : 116 - 116
  • [23] ABCG2/BCRP: Specific and Nonspecific Modulators
    Pena-Solorzano, Diana
    Stark, Simone Alexandra
    Koenig, Burkhard
    Augusto Sierra, Cesar
    Ochoa-Puentes, Cristian
    [J]. MEDICINAL RESEARCH REVIEWS, 2017, 37 (05) : 987 - 1050
  • [24] 2-Carboranylquinazoline: The Path to an ABCG2 Inhibitor
    Stockmann, Philipp
    Kuhnert, Lydia
    Zoerner, Lisa
    Honscha, Walther
    Hey-Hawkins, Evamarie
    [J]. CHEMMEDCHEM, 2023, 18 (11)
  • [25] ABCG2 as a therapeutic target candidate for gout
    Fujita, Kyoko
    Ichida, Kimiyoshi
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (02) : 123 - 129
  • [26] Structure of the human multidrug transporter ABCG2
    Nicholas M. I. Taylor
    Ioannis Manolaridis
    Scott M. Jackson
    Julia Kowal
    Henning Stahlberg
    Kaspar P. Locher
    [J]. Nature, 2017, 546 : 504 - 509
  • [27] Allelic Variants of ABCG2 and Gout Risk
    Stiburkova, Blanka
    Pavelcova, Katerina
    Zavada, Jakub
    Petru, Lenka
    Pavlikova, Marketa
    Matsuo, Hirotaka
    Merriman, Tony R.
    Pavelka, Karel
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [28] ABCG2蛋白的研究现状
    许义新
    朱海英
    胡以平
    [J]. 癌变·畸变·突变, 2007, (04) : 344 - 346
  • [29] Expression and function of ABCG2 and XIAP in glioblastomas
    Emery, Ivette F.
    Gopalan, Archana
    Wood, Stephanie
    Chow, Kin-hoe
    Battelli, Chiara
    George, Joshy
    Blaszyk, Hagen
    Florman, Jeffrey
    Yun, Kyuson
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2017, 133 (01) : 47 - 57
  • [30] Pharmacogenetics of ABCG2 and adverse reactions to gefitinib
    Cusatis, George
    Gregorc, Vanesa
    Li, Jing
    Spreafico, Anna
    Ingersoll, Roxann G.
    Verweij, Jaap
    Ludovini, Vienna
    Villa, Eugenio
    Hidalgo, Manuel
    Sparreboom, Alex
    Baker, Sharyn D.
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (23) : 1739 - 1742